Management of obesity and cardiometabolic risk - Role of phentermine/extended release topiramate

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2014, Pages 35-44

  Sweeting, Arianne N ^a   Tabet, Eddy ^a   Caterson, Ian D ^a,b   Markovic, Tania P ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Obesity; Phentermine topiramate extended release; Review; Safety and efficacy

Indexed keywords

HEMOGLOBIN A1C; LORCASERIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ABNORMAL FECES; ATTENTION DISTURBANCE; BIRTH DEFECT; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONFUSION; CONSTIPATION; CONTRACEPTION; DEFECATION URGENCY; DEPRESSION; DISEASE ASSOCIATION; DIZZINESS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FECES INCONTINENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; LANGUAGE DISABILITY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEMORY DISORDER; METABOLIC ACIDOSIS; MIGRAINE; MYOPIA; NAUSEA; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOPATHY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; TACHYCARDIA; TERATOGENICITY; VALVULAR HEART DISEASE; VISUAL DISORDER; XEROSTOMIA;

EID: 84894874002     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S38979     Document Type: Review

References (49)

1. Finucane MM, Stevens GA, Cowan MJ, et al; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9{dot operator}1 million participants. Lancet. 2011;377(9765):557-567.
2. Vasan RS, Pencina MJ, Cobain M, Freiberg MS, D'Agostino RB. Estimated risks for developing obesity in the Framingham Heart Study. Ann Intern Med. 2005;143(7):473-480.
3. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9): 1431-1437.
4. Bleich SN, Bennett WL, Gudzune KA, Cooper LA. Impact of physician BMI on obesity care and beliefs. Obesity (Silver Spring). 2012;20(5): 999-1005.
5. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763-778.
6. Whitlock G, Lewington S, Sherliker P, et al; Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-1096.
7. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16(6):397-415.
8. Poirier P, Giles TD, Bray GA, et al; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898-918.
9. James WP, Caterson ID, Coutinho W, et al; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-917.
10. Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med. 1997;337(9):602-606.
11. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-588.
12. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. Epub November 14, 2013.
13. Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation. 2012;125(13):1695-1703.
14. Lorello C, Goldfield GS, Doucet E. Methylphenidate hydrochloride increases energy expenditure in healthy adults. Obesity (Silver Spring). 2008;16(2):470-472.
15. Pasquali R, Casimirri F, Melchionda N, et al. Effects of chronic administration of ephidrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. Clin Sci (Lond). 1992;82(1):85-92.
16. Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf. 2012;11(3):459-471.
17. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-546.
18. Douglas A, Douglas JG, Robertson CE, Munro JF. Plasma phentermine levels, weight loss and side-effects. Int J Obes. 1983;7(6):591-595.
19. Hendricks EJ, Greenway FL. A study of abrupt phentermine cessation in patients in a weight management program. Am J Ther. 2011;18(4): 292-299.
20. Food and Drug Administration. Clinical Briefing Document, Endocrine and Metabolic Drugs Advisory Committee Meeting, February 22, 2012. New Drug Application 22580: VI-052 Qnexa (phentermine/topiramate). Silver Spring, MD: Food and Drug Administration; 2012 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292315.pdf. Accessed July 3, 2013.
21. Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther. 2009;330(2):558-566.
22. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95(3):189-199.
23. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res. 2000;8(9):656-663.
24. Tonstad S, Tykarski A, Weissgarten J, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol. 2005;96(2):243-251.
25. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41 Suppl 1:S3-S9.
26. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 2003;11(4):556-562.
27. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.
28. Brandes JL, Saper JR, Diamond M, et al; MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965-973.
29. Henry RR, Chilton R, Garvey WT. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications. 2013;27(5):508-518.
30. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003;27(12): 1437-1446.
31. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161.
32. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000;8(1):49-61.
33. Bays HE. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. Expert Rev Cardiovasc Ther. 2009;7(11):1429-1445.
34. Smith SR, Weissman NJ, Anderson CM, et al; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-256.
35. Fidler MC, Sanchez M, Raether B, et al; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-3077.
36. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7): 1426-1436.
37. Wyatt HR. Update on treatment strategies for obesity. J Clin Endocrinol Metab. 2013;98(4):1299-1306.
38. Ryan D, Peterson C, Troupin B, et al. Weight loss at 6 months with VI-0521 (PHEN/TPM combination) treatment. Obes Facts 2010:3146.
39. Robert M. Clinical Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting for phentermine/topiramate (Qnexa). Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingsMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218824.pdf (2010). Accessed August 9, 2013.
40. Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev Cardiovasc Ther. 2010;8(12):1777-1801.
41. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-342.
42. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012; 95(2):297-308.
43. Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012;35(11):1529-1539.
44. Margulis AV, Mitchell AA, Gilboa SM, et al. National birth defects prevention study. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207:405. e1-e7.
45. Hunt S, Russell A, Smithson WH, et al; UK Epilepsy and Pregnancy Register. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology. 2008;71(4):272-276.
46. Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol. 2009; 68(5):655-661.
47. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol. 1977;95(8):1378-1382.
48. Zhou YH et al. Effect of anti-obesity drug on cardiovascular risk factors: A systematic review and meta-analysis of randomised controlled trials. PLoS One. 2012;7(6):e39062.
49. Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol. 2013;9:467-478.